Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC
In patients with <i>EGFR</i>-mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).
Authors
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0001-7380-5510)
- Yong Fang (ORCID: https://orcid.org/0009-0005-6591-1248)
- Yongzhong Luo (ORCID: https://orcid.org/0000-0003-0770-0854)
- Junyou Ge (ORCID: https://orcid.org/0000-0002-6524-0078)
- Qiming Wang (ORCID: https://orcid.org/0000-0002-7813-2885)
- Yuju Bai (ORCID: https://orcid.org/0000-0003-2897-9997)
- Bin Yang (ORCID: https://orcid.org/0000-0002-6218-2773)
- Jiuwei Cui (ORCID: https://orcid.org/0000-0001-6496-7550)
- Xingya Li (ORCID: https://orcid.org/0009-0005-0711-5702)
- Wei Zheng (ORCID: https://orcid.org/0000-0001-6107-7261)
- Jiacheng Yang (ORCID: https://orcid.org/0000-0002-8475-2546)
- Xiaoping Jin (ORCID: https://orcid.org/0000-0003-3593-5853)
- Li Zhang (ORCID: https://orcid.org/0009-0001-3828-8113)
- Jian Fang (ORCID: https://orcid.org/0000-0003-3697-4563)
- Kai Li (ORCID: https://orcid.org/0000-0002-6895-0024)
- Wenfeng Fang
- Rui Ma
- Yun-Peng Yang
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Lin Wu (ORCID: https://orcid.org/0000-0003-3166-0530)
- Runxiang Yang (ORCID: https://orcid.org/0000-0003-3684-5892)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-2274-429X)
- Jie Hu (ORCID: https://orcid.org/0009-0001-5858-6169)
- Yanyan Xie (ORCID: https://orcid.org/0009-0004-6957-8131)
- Wei Jiang (ORCID: https://orcid.org/0000-0002-8315-339X)
- Wei Zuo (ORCID: https://orcid.org/0000-0003-2391-1678)
- Yan Yu (ORCID: https://orcid.org/0000-0001-5598-763X)
- Zhentian Liu (ORCID: https://orcid.org/0000-0003-4095-8670)
- Yu Yao
- Wu Zhuang
- Yina Diao
- Wenxiu Yao (ORCID: https://orcid.org/0009-0008-0812-5656)
- Fang Ma
- Liyan Jiang
Institutions
- Target (United States) (US)
- Shanghai Medical College of Fudan University (CN)
- Central South University (CN)
- Nanchang University (CN)
- University of Electronic Science and Technology of China (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Zunyi Medical University (CN)
- Jilin University (CN)
- Peking University (CN)
- Kunming Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Chest Hospital (CN)
- Peking University Cancer Hospital (CN)
- Mianyang Central Hospital (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Hunan Cancer Hospital (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Kelun Group (China) (CN)
- First Hospital of Jilin University (CN)
- Zhongshan Hospital (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Fujian Provincial Cancer Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Hubei Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Shandong First Medical University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Zhejiang University (CN)
- China Medical University (CN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1056/nejmoa2512071
- Citations
- 18
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 27.33